Evolution of the Average Target: Lazard

Evolution of the Target Price: Lazard

Changes in Analyst Recommendations: Lazard

c61e091dc0.yXrAWSf8l58Q_wRoD3w1aXGX86XWOk581TZtcBW6G-c.rCWNDn-l8qwox1QvZUUDJzLIicG9dgEf5wY9FlbXWrWQA6JsZq3yrFmWTQ~d15fcd101cf2408006e93a3ae36a4f44
07-24 Morgan Stanley Adjusts Price Target on Lazard to $44 From $47, Maintains Underweight Rating MT
07-10 BofA Adjusts Price Target on Lazard to $55 From $60 MT
07-09 Houlihan Lokey Estimates Cut by Morgan Stanley as Sponsor M&A Recovery Lags MT
07-09 Morgan Stanley Adjusts Price Target on Lazard to $47 From $53, Maintains Underweight Rating MT
05-04 UBS Adjusts Price Target on Lazard to $44 From $45, Maintains Neutral Rating MT
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
05-04 Morgan Stanley Lifts Price Target on Lazard to $53 From $52, Keeps Underweight Rating MT
04-14 Analyst recommendations: Biogen, Ford, Ge Vernova, Booking, Comcast… Zonebourse
04-10 BofA Securities Adjusts Price Target on Lazard to $63 From $65 MT
04-08 Wealth Brokers, Investment Banks Faced Uneven First-Quarter Activity, UBS Says MT
04-08 UBS Adjusts Price Target on Lazard to $45 From $48, Maintains Neutral Rating MT
04-08 Keefe, Bruyette & Woods Downgrades Lazard to Market Perform From Outperform, Adjusts Price Target to $47 From $62 MT
04-08 Analyst recommendations: Deere & Co, Verizon, Apollo Global Management, ServiceNow… Zonebourse
03-12 UBS Adjusts Lazard Price Target to $48 From $59, Maintains Neutral Rating MT
01-30 UBS Adjusts Price Target on Lazard Inc to $59 From $54, Maintains Neutral Rating MT
01-26 BofA Securities Initiates Coverage on Lazard With Buy Rating, $65 Price Target MT
01-06 Morgan Stanley Trims Price Target on Lazard to $59 From $61, Keeps Underweight Rating MT
24/10/25 Morgan Stanley Lifts Price Target on Lazard to $62 From $61, Keeps Underperform Rating MT
03/10/25 BMO Capital Initiates Coverage on Lazard With Market Perform Rating, $56 Price Target MT
18/09/25 Lazard, Inc. Appoints Geoffrey Porges as Managing Director in the Healthcare Advisory Group CI
25/08/25 Analyst recommendations: Alaska Air, American Airlines, Dr Horton, Dollar Tree, Williams-Sonoma… Zonebourse
25/08/25 Keefe Bruyette & Woods Upgrades Lazard to Outperform From Market Perform, Adjusts PT to $65 From $60 MT
23/06/25 Analyst recommendations: Boston Properties, Dow, DraftKings, Estee Lauder, Jefferies… Zonebourse
09/04/25 UBS Adjusts Price Target on Lazard to $38 From $54, Maintains Neutral Rating MT
03/02/25 UBS Adjusts Price Target on Lazard to $54 From $50, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+20.46%
+0.85%
+6.55%
+31.08%
+18.22%
+7.92%
+5.95%
+18.37%
+0.89%
Average +12.26%
Weighted average by Cap. +12.98%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
42.38USD
Average target price
47.12USD
Spread / Average Target
+11.20%
High Price Target
60.00USD
Spread / Highest target
+41.58%
Low Price Target
40.00USD
Spread / Lowest Target
-5.62%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Morgan Stanley
BofA Securities
UBS
Keefe Bruyette & Woods
BMO Capital
Wolfe Research
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
42.38USD
Average target price
47.12USD
Spread / Average Target
+11.20%

Quarterly revenue - Rate of surprise